| Endocrine therapy |
|
| No |
86 (19.5) |
| TAM of synchronous carcinoma |
96 (21.8) |
| TAM of metachronous carcinoma |
21 (4.8) |
| AI of synchronous carcinoma |
95 (21.6) |
| AI of metachronous carcinoma |
26 (5.9) |
| Other |
11 (2.5) |
| NA |
105 (23.9) |
| Chemotherapy |
|
| No |
96 (21.8) |
| Neoadjuvant chemotherapy of synchronous carcinoma |
72 (16.4) |
| Neoadjuvant chemotherapy of metachronous carcinoma |
5 (1.1) |
| Adjuvant chemotherapy of synchronous carcinoma |
132 (30.0) |
| Adjuvant chemotherapy of metachronous carcinoma |
46 (10.5) |
| NA |
89 (20.2) |
| Radiotherapy |
|
| No |
208 (47.3) |
| Radiotherapy of synchronous carcinoma |
69 (15.7) |
| Radiotherapy of metachronous carcinoma |
26 (5.9) |
| NA |
137 (31.1) |
| Targeted therapy- HER2-positive |
|
| No |
32 (40.0) |
| Targeted therapy of synchronous carcinoma |
21 (26.3) |
| Targeted therapy of metachronous carcinoma |
5 (6.3) |
| NA |
22 (27.5) |
